Newly developed retatrutide, a combined-action treatment targeting equally GLP-1 and GIP receptors, is generating considerable buzz within the medical community. Early clinical trials have revealed substantial reductions in body weight and gains in metabolic markers for people with excess weight . Scientists believe this ground-breaking approac… Read More